Updates from the San Antonio Breast Cancer Symposium 2013 HER2+ Breast Cancer Julie R. Gralow, M.D....
If you can't read please download the document
Updates from the San Antonio Breast Cancer Symposium 2013 HER2+ Breast Cancer Julie R. Gralow, M.D. Director and Jill Bennett Professor of Breast Medical
Updates from the San Antonio Breast Cancer Symposium 2013 HER2+
Breast Cancer Julie R. Gralow, M.D. Director and Jill Bennett
Professor of Breast Medical Oncology Professor of Global Health
University of Washington School of Medicine Fred Hutchinson Cancer
Research Center Seattle Cancer Care Alliance
Slide 2
HER-2 Over-Expressing Breast Cancer cell division HER-2 nucleus
cancer cell Trastuzumab Anti-HER-2 Antibody HER-2 Oncogene:
amplified and overexpressed in 20- 25% of breast cancer Lapatinib
Dual HER-1/HER-2 Tyrosine Kinase Inhibitor Pertuzumab Anti-HER-2
Antibody T-DM1 Antibody-Drug Conjugate
Slide 3
APT Study: Phase II Study of Paclitaxel + Trastuzumab as
Adjuvant Therapy for Small, Node-negative HER2+ Breast Cancer
Tolaney SM et al, SABCS 2013, abstract #S1-04 Randomized adjuvant
HER2+ trials included few small, lymph node negative breast cancers
Patients: 406 pts with node-negative, HER2+ breast cancer, < 3
cm 2/3 ER+, 20% < 0.5 cm Treatment: Paclitaxel and trastuzumab
weekly x 12, followed by 9 months of single agent trastuzumab
Results: 3.6 years median follow-up ): 2 distant, 4 locoregional, 3
contralateral breast cancers, 1 non- breast cancer death (ovarian
ca) 10 recurrences/deaths (2.5%): 2 distant, 4 locoregional, 3
contralateral breast cancers, 1 non- breast cancer death (ovarian
ca) 3 year DFS 98.7%
Slide 4
APT Study: Phase II Study of Paclitaxel + Trastuzumab as
Adjuvant Therapy for Small, Node-negative HER2+ Breast Cancer
Tolaney SM et al, SABCS 2013, abstract #S1-04 Toxicity: 2
symptomatic CHF (resolved on stopping trastuzumab) 13 asymptomatic
declines in LVEF (able to resume trastuzumab in 11) Conclusion:
Paclitaxel plus trastuzumab can be considered a reasonable approach
for majority of patients with small, lymph node negative, HER2+
breast cancer
Slide 5
HER2 Therapy Combinations Neo ALTTO: Preop HER2+ Baselga J et
al, Lancet 379:633-640, 2012 Invasive, operable HER2+ breast cancer
T > 2 cm N=450 lapatinib trastuzumab lapatinib trastuzumab
FECX3FECX3 SURGERYSURGERY RANDOMIZERANDOMIZE Lapatinib 1500 mg/d
Trastuzumab weekly Lapatinib 1000 to 750 trastuzumab paclitaxel 80
mg/m2 paclitaxel paclitaxel pCR
Slide 6
Neo ALTTO: Survival Follow-up Analysis Piccart M et al, SABCS
2013 abstract #S1-01 Lapatanib + Trastuzumab TrastuzumabLapatinib 3
yr EFS (all)84%78% HR+83%80%86% HR-86%72%70% 3 yr OS (all)95%90%93%
HR+97%94%93% HR-93%87%93% None statistically significant
Slide 7
Neo ALTTO: EFS and OS by pCR Piccart M et al, SABCS 2013
abstract #S1-01
Slide 8
Neo ALTTO Survival Follow-up Analysis: Conclusions Underpowered
to detect moderate EFS and OS differences, await results of ALTTO
adjuvant trialUnderpowered to detect moderate EFS and OS
differences, await results of ALTTO adjuvant trial Patients who
achieved pCR had significantly better EFS and OS compared with no
pCRPatients who achieved pCR had significantly better EFS and OS
compared with no pCR HER2+/ER- disease different from HER2/ER+
diseaseHER2+/ER- disease different from HER2/ER+ disease
Slide 9
Combined HER-2 Targeted Therapy BIG 2.06/N063D Adjuvant HER2+
Trial (ALTTO) Soon to Report PIs: M Piccart, E Perez HER2+ BC
Tumors 1 cm after completion of anthracycline based therapy with
LVEF 50% RANDOMIZERANDOMIZE (paclitaxel) trastuzumab (trast for 1
yr) (paclitaxel) lapatinib (lap for 1 yr) (paclitaxel) trastuzumab+
lapatinib (trast + lap for 1 yr) (paclitaxel) trastuzumab (12
weeks), 6-week wash out, lapatinib (34 weeks) N= 8,000
Slide 10
TRIO Trial: Phase II Trial of Preoperative Trastuzumab,
Lapatinib or Combination Hurvitz S et al, SABCS 2013, abstract
#S1-02 Lapatinib 21 days Trastuzumab 1 dose Lapatinib 21 days
Trastuzumab 1 dose TCH x 6 cycles TCL x 6 cycles TCHL x 6 cycles
surgery biopsy HER2+ invasive breast cancer Stage I- III N=130
Slide 11
TRIO Trial: Phase II Trial of Preoperative Trastuzumab,
Lapatinib or Combination Hurvitz S et al, SABCS 2013, abstract
#S1-02
Slide 12
pCR similar in TCH and TCHL armspCR similar in TCH and TCHL
arms Differs from other preop studies Numbers in each arm very
small Addition of lapatinib increased toxicity, limiting ability of
patients to receive planned therapyAddition of lapatinib increased
toxicity, limiting ability of patients to receive planned therapy
Molecular analyses ongoing to evaluate profiles of non-
respondersMolecular analyses ongoing to evaluate profiles of non-
responders
Slide 13
BETH: Randomized Phase III Trial of Adjuvant Bevacizumab in
HER2+ Breast Cancer Slamon D et al, SABCS 2-13, abstract #S1-03
Cohort 1 Non-Anthracycline TCH H Cohort 2 Anthracycline TH FEC H
Node positive or high-risk node negative HER2+ Arm 1A TCH H Arm 1B
TCHBev HBev Arm 2A TH FEC H Arm 2B THBev FEC HBev N= 3231 N=
278
Slide 14
BETH: Randomized Phase III Trial of Adjuvant Bevacizumab in
HER2+ Breast Cancer Slamon D et al, SABCS 2-13, abstract #S1-03
IDFSOS No Bevacizumab92%96% + Bevacizumab92%97% Median Follow-up 38
months 1 year of adjuvant bevacizumab added to chemo and
trastuzumab does not improve IDFS or OS
Slide 15
BETH: Randomized Phase III Trial of Adjuvant Bevacizumab in
HER2+ Breast Cancer Slamon D et al, SABCS 2-13, abstract #S1-03
Chemo/TrastuzumabChemo/Trastuzumab /Bevacizumab Hypertension4%19%
Thromboembolic event 2%3% Bleeding